Services to deliver Onasemnogene abeparvovec/Zolgensma
NHS England is seeking to commission a service to deliver Onasemnogene abeparvovec/Zolgensma from four providers in England. It is currently anticipated that there may be one provider to cover the North of England, one to cover the Midlands, one to cover the South of England plus one other. The commissioner is by no means fixed on this geographical spread as the quality of the service provision is the most important factor.
Buyer
NHS England - Specialised Commissioning
Value
£6,000,000
Published
30 Jun 2021
Closes
8 Mar 2021
Procurement details
Source
Find a Tender
Region
United Kingdom
Procurement method
Open
Category
Services
Contract starts
Not provided
Contract ends
Not provided
CPV classifications
85000000
Health and social work services
85100000
Health services
85140000
Miscellaneous health services
Lots
Lot 1 Services to deliver Onasemnogene abeparvovec/Zolgensma
£6,000,000
Spinal muscular atrophy, or SMA, is a rare genetic disorder that causes muscle weakness and progressive loss of movement. It is most commonly caused by defects in the gene SMN1. Onasemnogene abeparvovec (Zolgensma, AveXis) is a single-use gene replacement therapy made of a viral vector that has been modified to contain the primary gene for the human survival...
Delivery: United Kingdom
Documents
No document metadata is available for this public record.
Contains public sector information licensed under the Open Government Licence v3.0.